Skip to content

Monitoring and prognostic value of serum Epstein-Barr virus DNA in patients with nasopharyngeal carcinoma: a multi-center, single-arm, prospective study

Monitoring and prognostic value of serum Epstein-Barr virus DNA in patients with nasopharyngeal carcinoma: a multi-center, single-arm, prospective study

Status
Active, not recruiting
Phases
Phase 2
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500103347
Enrollment
Unknown
Registered
2025-05-28
Start date
2025-06-01
Completion date
Unknown
Last updated
2025-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nasopharyngeal carcinoma

Interventions

Observation group:None

Sponsors

The First Affiliated Hospital of Xiamen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. NPC patients confirmed by pathology (including keratinized squamous cell carcinoma, non-keratinized differentiated NPC, and non-keratinized undifferentiated NPC); 2. Confirmation of untreated, non-newly diagnosed metastatic NPC by radiologic evaluation; 3. Receiving standard treatment based on IMRT; 4. No history of other malignant tumors; 5. Male or female, older than 18 years old; 6. No serious heart, lung and other important organ dysfunction; 7. Eastern Cooperative Oncology Group (ECOG) score <= 2; 8. Serum EBV DNA records before and after treatment and during follow-up were complete, and relevant follow-up data were complete.

Exclusion criteria

Exclusion criteria: 1. Patients who cannot cooperate with regular follow-up due to psychological, social, family and geographical reasons; 2. Concurrently receiving investigational treatment in other clinical studies (in the treatment phase of the clinical study); 3. Patients with severe uncontrolled infection, medical diseases, or known primary immunodeficiency diseases; 4. Important organ dysfunction, decompensated heart, lung, kidney, liver failure, unable to tolerate radiotherapy, chemotherapy, immunotherapy, etc. 6. Patients with incomplete data from diagnosis to receiving systemic treatment and follow-up period.

Design outcomes

Primary

MeasureTime frame
Positive Predictive Value;Negative Predictive Value;

Countries

China

Contacts

Public ContactWu Sangang

The First Affiliated Hospital of Xiamen University

uno12345@163.com+86 592 2139531

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026